ScienceDaily: Latest Science News: Potential new target to treat malignant pleural mesothelioma

ScienceDaily: Latest Science News

Breaking science news and articles on global warming, extrasolar planets, stem cells, bird flu, autism, nanotechnology, dinosaurs, evolution -- the latest discoveries in astronomy, anthropology, biology, chemistry, climate and environment, computers, engineering, health and medicine, math, physics, psychology, technology, and more -- from the world's leading universities and research organizations.

Potential new target to treat malignant pleural mesothelioma
http://feeds.sciencedaily.com/~r/sciencedaily/~3/q3ZPfjVFZ5M/130725125449.htm
Jul 25th 2013, 16:54

July 25, 2013 — Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis. Increased understanding of the molecular basis for the diverse signaling pathways involved in cancer progression should promote the discovery of novel biomarkers for early diagnosis and potentially lead to more effective therapeutic tools for the disease.

Share This:






In the September issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO), researchers conclude that Ephrin (EPH) B2 seems to play an important role in malignant pleural mesothelioma cell lines and tumors.
Using expression arrays, researchers from the New York University Langone Medical Center looked at EPHB2 in 34 malignant pleural mesothelioma tumors , and found it significantly elevated in tumor tissue compared with matched normal peritoneum. They found EPHB2 overexpressed in all malignant pleural mesothelioma cell lines, but not in benign mesothelial cells. EPHB2 is also significantly elevated in malignant pleural mesothelioma tumor tissue compared with matched normal peritoneum.
Researchers believe, "targeting EPHB2 might provide a novel therapy to improve the prognosis in people suffering from malignant pleural mesothelioma. Further investigation in vitro using specific inhibitors of EPHB2 is required to determine the importance of EPHB2 and its interactions with other members of the receptor kinases and their ligands to prove its role as a marker of progression or worse prognosis for malignant pleural mesothelioma.
The lead author is Chandra Goparaju. Co-authors include IASLC members Dr. Jessica Donington and Dr. Harvey Pass.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.





Note: If no author is given, the source is cited instead.

This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers. Five Filters recommends: 'You Say What You Like, Because They Like What You Say' - http://www.medialens.org/index.php/alerts/alert-archive/alerts-2013/731-you-say-what-you-like-because-they-like-what-you-say.html



You are receiving this email because you subscribed to this feed at http://blogtrottr.com

If you no longer wish to receive these emails, you can unsubscribe here:
http://blogtrottr.com/unsubscribe/cz0/tSbHWJ